CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:
Net income	$ 237,898	$ 327,556
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	38,551	29,912
Non-cash compensation expense	225,784	143,217
Non-cash interest expense	15,629	17,316
Losses on Extinguishment of Debt	10,787	0
Other non-cash charges and expenses, net	12,844	15,710
Deferred taxes	(50,466)	82,890
Changes in assets and liabilites
Decrease (increase) in Sanofi, Bayer HealthCare, and trade accounts receivable	27,713	(350,809)
Increase in Inventories	(50,917)	(36,742)
(Increase) decrease in prepaid expenses and other assets	(28,850)	3,738
Increase (decrease) in deferred revenue	29,395	(20,815)
Increase in accounts payable, accrued expenses and other liabilities	76,506	94,894
Total adjustments	306,976	(20,689)
Net cash provided by operating activities	544,874	306,867
Cash flows from investing activities:
Purchases of marketable securities	(478,436)	(477,312)
Sales or maturities of marketable securities	216,478	319,152
Capital expenditures	(215,464)	(87,347)
Net cash used in investing activities	(477,422)	(245,507)
Cash flows from financing activities:
Payments in connection with facility and capital lease obligations	(810)	(1,625)
Repayments of convertible senior notes	(61,125)	0
Payments in connection with deduction of outstanding warrants	(143,041)	0
Proceeds from issuance of Common Stock	80,804	41,718
Payments in connection with Common Stock tendered for employee tax obligations	(175,866)	(166,358)
Excess tax benefit from stock-based compensation	343,532	97,840
Net cash provided by (used in) financing activities	43,494	(28,425)
Net increase in cash and cash equivalents	110,946	32,935
Cash and cash equivalents at beginning of period	535,608	230,276
Cash and cash equivalents at end of period	$ 646,554	$ 263,211